Berlin, Germany
Silica Corpora, founded in 2022 and headquartered in Germany, presents an innovative approach to the field of AI-driven Biopharma and Life Sciences. Their slogan, “In Silica Corpora we design the next generation of Antibody Therapeutics using Generative AI,” encapsulates their pioneering focus on utilizing Generative AI to design antibody drug candidates expediently, emphasizing "Design, not Discovery"—a process they assert reduces lead generation timelines from years to mere days.
The company's latest funding achievement was a €142.50K grant investment on 10 June 2023 from EXIST, reinforcing their potential and the interest they generate within the scientific and investment communities. With a focus on speeding up therapeutic development, Silica Corpora positions itself strategically at the nexus of technological innovation and biopharmaceutical advancement—offering a compelling proposition for investors seeking to capitalize on cutting-edge drug development solutions.
